Agios Pharmaceuticals, Inc. (0HB0.L)
USD 26.46
(-7.16%)
USD 26.46
(-7.16%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 937.11 Million USD | -24.35% |
| 2022 | 1.23 Billion USD | -13.84% |
| 2021 | 1.43 Billion USD | 68.56% |
| 2020 | 852.95 Million USD | -4.24% |
| 2019 | 890.74 Million USD | 3.76% |
| 2018 | 858.45 Million USD | 39.72% |
| 2017 | 614.39 Million USD | -0.76% |
| 2016 | 619.09 Million USD | 47.38% |
| 2015 | 420.06 Million USD | -14.6% |
| 2014 | 491.9 Million USD | 144.48% |
| 2013 | 201.2 Million USD | 46.86% |
| 2012 | 137 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 773.06 Million USD | -9.02% |
| 2024 Q3 | 1.79 Billion USD | 131.78% |
| 2024 Q1 | 849.7 Million USD | -9.33% |
| 2023 Q3 | 1 Billion USD | -7.18% |
| 2023 FY | 937.11 Million USD | -24.35% |
| 2023 Q4 | 937.11 Million USD | -6.96% |
| 2023 Q1 | 1.15 Billion USD | -7.06% |
| 2023 Q2 | 1.08 Billion USD | -5.75% |
| 2022 Q3 | 1.18 Billion USD | -5.76% |
| 2022 Q2 | 1.25 Billion USD | -6.24% |
| 2022 Q1 | 1.33 Billion USD | -7.09% |
| 2022 FY | 1.23 Billion USD | -13.84% |
| 2022 Q4 | 1.23 Billion USD | 4.95% |
| 2021 Q2 | 1.87 Billion USD | -24.67% |
| 2021 Q4 | 1.43 Billion USD | -6.73% |
| 2021 Q3 | 1.54 Billion USD | -17.77% |
| 2021 FY | 1.43 Billion USD | 68.56% |
| 2021 Q1 | 2.48 Billion USD | 191.74% |
| 2020 Q3 | 908.44 Million USD | -6.93% |
| 2020 FY | 852.95 Million USD | -4.24% |
| 2020 Q4 | 852.95 Million USD | -6.11% |
| 2020 Q1 | 799.73 Million USD | -10.22% |
| 2020 Q2 | 976.14 Million USD | 22.06% |
| 2019 Q2 | 783.87 Million USD | -4.65% |
| 2019 FY | 890.74 Million USD | 3.76% |
| 2019 Q4 | 890.74 Million USD | 27.5% |
| 2019 Q3 | 698.61 Million USD | -10.88% |
| 2019 Q1 | 822.13 Million USD | -4.23% |
| 2018 Q4 | 858.45 Million USD | -7.6% |
| 2018 Q1 | 1.04 Billion USD | 69.29% |
| 2018 FY | 858.45 Million USD | 39.72% |
| 2018 Q2 | 998.23 Million USD | -4.03% |
| 2018 Q3 | 929.07 Million USD | -6.93% |
| 2017 Q2 | 760.6 Million USD | 36.48% |
| 2017 FY | 614.39 Million USD | -0.76% |
| 2017 Q4 | 614.39 Million USD | -10.59% |
| 2017 Q1 | 557.31 Million USD | -9.98% |
| 2017 Q3 | 687.2 Million USD | -9.65% |
| 2016 Q1 | 396.11 Million USD | -5.7% |
| 2016 Q3 | 672.04 Million USD | 20.52% |
| 2016 Q2 | 557.6 Million USD | 40.77% |
| 2016 Q4 | 619.09 Million USD | -7.88% |
| 2016 FY | 619.09 Million USD | 47.38% |
| 2015 Q4 | 420.06 Million USD | -6.46% |
| 2015 Q3 | 449.08 Million USD | -5.33% |
| 2015 Q2 | 474.38 Million USD | 0.01% |
| 2015 Q1 | 474.33 Million USD | -3.57% |
| 2015 FY | 420.06 Million USD | -14.6% |
| 2014 Q1 | 181.91 Million USD | -9.59% |
| 2014 Q3 | 269.6 Million USD | -0.89% |
| 2014 Q4 | 491.9 Million USD | 82.45% |
| 2014 FY | 491.9 Million USD | 144.48% |
| 2014 Q2 | 272.03 Million USD | 49.54% |
| 2013 Q1 | 125.85 Million USD | -8.14% |
| 2013 Q4 | 201.2 Million USD | -8.15% |
| 2013 Q3 | 219.06 Million USD | 96.91% |
| 2013 FY | 201.2 Million USD | 46.86% |
| 2013 Q2 | 111.25 Million USD | -11.6% |
| 2012 Q4 | 137 Million USD | 0.0% |
| 2012 FY | 137 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -12.676% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -20.471% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -466.221% |
| bluebird bio, Inc. | 619.16 Million USD | -51.353% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -644.666% |
| Imunon, Inc. | 21.91 Million USD | -4175.55% |
| Editas Medicine, Inc. | 499.15 Million USD | -87.742% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 96.488% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 72.073% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 21.822% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 71.178% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 33.489% |
| Verastem, Inc. | 149.71 Million USD | -525.922% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 98.844% |
| Waters Corporation | 4.62 Billion USD | 79.746% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.051% |
| Biogen Inc. | 26.84 Billion USD | 96.509% |
| Nektar Therapeutics | 398.03 Million USD | -135.437% |
| Perrigo Company plc | 10.8 Billion USD | 91.33% |
| Dynavax Technologies Corporation | 997.09 Million USD | 6.015% |
| Illumina, Inc. | 10.11 Billion USD | 90.732% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -3214.604% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -20.089% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -321.165% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1326.576% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 86.303% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -466.851% |
| Evolus, Inc. | 188.99 Million USD | -395.835% |
| Adicet Bio, Inc. | 207.29 Million USD | -352.07% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -374.718% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 97.167% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -355.363% |
| FibroGen, Inc. | 423.52 Million USD | -121.264% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 91.293% |
| OPKO Health, Inc. | 2.01 Billion USD | 53.417% |
| Homology Medicines, Inc. | 47.05 Million USD | -1891.453% |
| Geron Corporation | 394.07 Million USD | -137.801% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 75.531% |
| Exelixis, Inc. | 2.94 Billion USD | 68.151% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -154.313% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -506.997% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 27.968% |
| Zoetis Inc. | 14.28 Billion USD | 93.44% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -59.31% |
| Abeona Therapeutics Inc. | 64 Million USD | -1364.201% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 95.877% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -1574.95% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 68.659% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 71.294% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -50.779% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 45.934% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 10.687% |
| Insmed Incorporated | 1.32 Billion USD | 29.531% |
| TG Therapeutics, Inc. | 329.58 Million USD | -184.331% |
| Incyte Corporation | 6.78 Billion USD | 86.182% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 48.928% |